About C3J Therapeutics
C3J Therapeutics is a company based in Los Angeles (United States) founded in 2006. C3J Therapeutics has raised $214.5 million across 9 funding rounds from investors including HHS, Renaissance Acquisition Holdings and Delta Dental. The company has 60 employees as of December 31, 2021. C3J Therapeutics offers products and services including Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03. C3J Therapeutics operates in a competitive market with competitors including Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others.
- Headquarter Los Angeles, United States
- Employees 60 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name C3j Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$214.5 M (USD)
in 9 rounds
-
Latest Funding Round
$19 M (USD), Series D
Dec 14, 2016
-
Investors
HHS
& 2 more
-
Employee Count
60
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of C3J Therapeutics
C3J Therapeutics offers a comprehensive portfolio of products and services, including Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03.
Technology for targeting and destroying bacterial pathogens.
System for developing engineered phages against infections.
Therapeutic for specific bacterial infections and resistance.
Advanced phage therapy for combating resistant bacteria.
Funding Insights of C3J Therapeutics
C3J Therapeutics has successfully raised a total of $214.5M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $19 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in C3J Therapeutics
C3J Therapeutics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Renaissance Acquisition Holdings and Delta Dental.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Online gaming and gambling platform
|
Locked | Locked | Locked | |
|
Dental insurance plans are offered by Delta Dental nationwide.
|
Locked | Locked | Locked |
Investor details for C3J Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by C3J Therapeutics
Investment portfolio details for C3J Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - C3J Therapeutics
Detailed financials for C3J Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
C3j Therapeutics Comparisons
Peer comparison for C3J Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of C3J Therapeutics
C3J Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, MeMed, GenMark Diagnostics, Sunbird Bio and T2 Biosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
|
| Locked | Locked | Locked |
Diagnostic technologies for infectious, cancer, and neurological diseases are developed.
|
|
| Locked | Locked | Locked |
Miniaturized MRI platforms for clinical diagnostics are developed.
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
Detailed competitors of C3J Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on C3j Therapeutics
Complete news archive for C3J Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C3J Therapeutics
C3J Therapeutics was founded in 2006 and raised its 1st funding round 3 years after it was founded.
C3J Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
C3J Therapeutics is a funded company, having raised a total of $214.5M across 9 funding rounds to date.
As of Dec 31, 2021, the latest employee count at C3J Therapeutics is 60.
C3J Therapeutics was established in 2006 in Los Angeles, United States, with operations centered on the biotechnology sector. Specifically targeted antimicrobial peptides (STAMPs) are advanced for treating and preventing conditions linked to microbial dysbiosis. Key pipeline elements include C16G2, advanced to Phase 2 for dental caries prevention, and CD17-DL, in Phase 1 for C. difficile infection management. A PCR-based diagnostic for S. mutans detection is also in development.
C3J Therapeutics's top competitors include Visby Medical, Inflammatix and MeMed.
C3J Therapeutics offers Bacteriophages, Synthetic Phage Platform, AP-PA02, and AP-PA03.
C3J Therapeutics has 3 investors. Key investors include HHS, Renaissance Acquisition Holdings, and Delta Dental.